Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer-Reference-Cited by-同舟云学术

Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer

Published:2016-09 Issue:3 Volume:15 Page:264-276
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Colloca Giuseppe^ORCID,Venturino Antonella^ORCID,Guarneri Domenico

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference64 articles.

1. Cancer statistics, 2014;Siegel;CA Cancer J Clin,2014

2. European cancer mortality predictions for the year 2014;Malvezzi;Ann Oncol,2014

3. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial;Burris;J Clin Oncol,1997

4. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of phase 3 trials;Bria;Cancer,2007

5. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer;Heinemann;BMC Cancer,2008

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surrogate Endpoints in Oncology: Overview of Systematic Reviews and Their Use for Health Decision Making in Mexico;Value in Health Regional Issues;2021-12

2. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework;Health Technology Assessment;2021-12

3. Systemic Inflammation Scores Predict the Activity of First-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma;Cancer Investigation;2020-12-22

4. A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer;British Journal of Cancer;2020-09-11

5. A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology;European Journal of Cancer;2019-01